The Wegovy process from first consultation to weekly injection

Is Wegovy right for your situation? The decision before the process begins

The Wegovy process only makes sense if the medicine suits your circumstances, so the first real step is honest self-assessment before you even speak to a prescriber. Wegovy is licensed in the UK for adults, it is not approved for anyone under 18, during pregnancy, while breastfeeding, or when trying to conceive. It requires a BMI of at least 30, or at least 27 alongside a condition such as hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance, a detail worth raising at assessment.

Beyond the numbers, you need to be genuinely committed to the lifestyle component. Semaglutide, the active ingredient in Wegovy, reduces appetite, it does not replace a reduced-calorie diet or increased activity, and the licence specifically pairs it with both. The STEP 1 trial published in the New England Journal of Medicine (68 weeks, semaglutide 2.4mg) reported an average body-weight reduction of around 15%, but that was in participants following structured lifestyle support alongside the medicine.

Your prescriber will also need to know about any personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, and any other GI conditions. That conversation shapes whether Wegovy is appropriate for you specifically, and if you want to understand who produces Wegovy and how it is manufactured, that background can also inform your confidence in the medicine before you begin. A real decision, not a rubber stamp.

How the dose titration process unfolds over the first five months

Once a prescriber confirms suitability, the titration schedule begins. Wegovy starts at 0.25mg once weekly for the first four weeks. This is purely a tolerability step, its job is to let your body adjust to semaglutide before any meaningful appetite suppression takes hold. After that, the dose moves to 0.5mg, then 1.0mg, then 1.7mg, and finally 2.4mg, each step roughly four weeks apart. The full journey to maintenance dose takes around five months if every step goes smoothly.

Not everyone reaches 2.4mg on that schedule. Some people stay longer at a lower dose if side effects are significant, and the prescriber's guidance (not a fixed timetable) governs each move. If you are already established on the injection and considering the newer 7.2mg option approved by the MHRA in April 2026, that too is a clinical conversation, not an automatic next step.

Practically speaking, each Wegovy pen is pre-filled and pre-set to the correct dose for that stage of your treatment. You inject once a week, into the abdomen, thigh or upper arm, rotating sites. Storage is in the fridge between 2°C and 8°C, refer to the Patient Information Leaflet for exact details on the room-temperature window, because the allowance is specific and matters if you travel. The practical benefits people report often include reduced hunger between meals, fewer cravings and a changed relationship with food rather than willpower, though individual experience varies.

Side effects during the process and when to seek help

The side-effect profile of Wegovy is dominated by gastrointestinal symptoms: nausea, vomiting, diarrhoea, constipation, indigestion and burping are the most commonly reported. They tend to peak in the first few days after a new dose, then ease as your body adjusts. Most people find them manageable, particularly if they eat smaller portions, stay hydrated and avoid fatty or heavy meals.

There are rarer but more serious signals to know before you start. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but potentially serious side effect of GLP-1 medicines: severe, persistent stomach pain that radiates to the back, with or without vomiting, warrants urgent medical attention. Other symptoms requiring prompt review include signs of a serious allergic reaction, gallbladder problems, or significant dehydration from persistent vomiting or diarrhoea. The NHS medicines page for semaglutide covers a full side-effect list alongside the signs that need immediate care.

You can report any suspected side effect through the MHRA's Yellow Card scheme. It is worth bookmarking before you start, not after.

The process through a regulated UK pharmacy versus the NHS route

Wegovy is available on the NHS, but the NICE recommendation (TA875) restricts it to specialist weight management services for a maximum of two years, with multidisciplinary support, and for most people that means a waiting list. The private route via a regulated online pharmacy removes the waiting list but requires the same clinical rigour: a legitimate prescriber assessment, identity verification, and a real prescription.

At a regulated pharmacy like nume (that is spelled with a u) a GPhC-registered Independent Prescriber reviews your consultation the same day. Orders placed before 12pm on a weekday are dispatched that afternoon once clinically approved, arriving with DPD the next working day in plain, unmarked packaging. There are no subscriptions and no auto-renewals; every repeat order goes through a fresh clinical review. You can verify any online pharmacy on the GPhC register before you hand over any personal information. If a seller offers semaglutide without a prescriber assessment, that is a legal and safety red flag, the MHRA has repeatedly warned about counterfeit pens sold this way.

For a detailed look at what Wegovy costs privately in the UK, including what a legitimate price should include, that information is on our pricing page. The short version: any price that does not include clinical assessment and prescription is not the full picture. If you have further questions about the process, our FAQs cover the most common ones, and the weight-loss treatment overview sets out the broader options alongside Wegovy.